Deroy & Devereaux Private Investment Counsel Inc. Lowers Stock Holdings in Cigna Group $CI

Deroy & Devereaux Private Investment Counsel Inc. trimmed its position in Cigna Group (NYSE:CI) by 0.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 75,014 shares of the health services provider’s stock after selling 289 shares during the period. Deroy & Devereaux Private Investment Counsel Inc.’s holdings in Cigna Group were worth $24,798,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in Cigna Group by 10.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,056,806 shares of the health services provider’s stock valued at $3,966,690,000 after purchasing an additional 1,094,327 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Cigna Group by 0.9% in the first quarter. Massachusetts Financial Services Co. MA now owns 11,654,993 shares of the health services provider’s stock valued at $3,834,493,000 after purchasing an additional 98,715 shares in the last quarter. Dodge & Cox raised its stake in Cigna Group by 1.3% in the first quarter. Dodge & Cox now owns 8,889,733 shares of the health services provider’s stock valued at $2,924,722,000 after purchasing an additional 117,125 shares in the last quarter. GQG Partners LLC raised its stake in Cigna Group by 21.5% in the first quarter. GQG Partners LLC now owns 4,886,674 shares of the health services provider’s stock valued at $1,607,716,000 after purchasing an additional 865,092 shares in the last quarter. Finally, Valeo Financial Advisors LLC raised its stake in Cigna Group by 86,071.1% in the second quarter. Valeo Financial Advisors LLC now owns 3,475,282 shares of the health services provider’s stock valued at $1,148,859,000 after purchasing an additional 3,471,249 shares in the last quarter. 86.99% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CI shares. Wall Street Zen downgraded shares of Cigna Group from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cigna Group in a research note on Wednesday, October 8th. The Goldman Sachs Group assumed coverage on shares of Cigna Group in a research report on Tuesday. They set a “buy” rating and a $370.00 price target on the stock. Robert W. Baird set a $372.00 price target on shares of Cigna Group in a research report on Thursday, August 14th. Finally, Deutsche Bank Aktiengesellschaft set a $415.00 price target on shares of Cigna Group and gave the company a “buy” rating in a research report on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $372.53.

Insider Activity at Cigna Group

In other news, insider Nicole S. Jones sold 28,526 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $300.00, for a total value of $8,557,800.00. Following the transaction, the insider owned 25,648 shares in the company, valued at approximately $7,694,400. This trade represents a 52.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian C. Evanko sold 5,368 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $300.00, for a total transaction of $1,610,400.00. Following the completion of the transaction, the insider owned 51,182 shares in the company, valued at $15,354,600. This represents a 9.49% decrease in their position. The disclosure for this sale can be found here. 0.70% of the stock is currently owned by company insiders.

Cigna Group Stock Up 2.2%

Shares of Cigna Group stock opened at $301.91 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.71 and a current ratio of 0.71. Cigna Group has a 52-week low of $256.89 and a 52-week high of $358.88. The stock has a market capitalization of $80.59 billion, a price-to-earnings ratio of 16.48, a P/E/G ratio of 0.87 and a beta of 0.45. The company’s 50 day moving average price is $295.86 and its 200-day moving average price is $308.87.

Cigna Group (NYSE:CI) last issued its earnings results on Thursday, July 31st. The health services provider reported $7.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.15 by $0.05. Cigna Group had a net margin of 1.92% and a return on equity of 18.80%. The firm had revenue of $67.13 billion for the quarter, compared to analysts’ expectations of $62.61 billion. During the same quarter last year, the business earned $6.72 earnings per share. The business’s revenue was up 11.0% on a year-over-year basis. Cigna Group has set its FY 2025 guidance at 29.600- EPS. Equities research analysts forecast that Cigna Group will post 29.77 EPS for the current year.

Cigna Group Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 18th. Stockholders of record on Thursday, September 4th were issued a $1.51 dividend. The ex-dividend date was Thursday, September 4th. This represents a $6.04 annualized dividend and a dividend yield of 2.0%. Cigna Group’s dividend payout ratio (DPR) is currently 32.97%.

Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.